Search

Displaying results 3671 - 3680 of 9333 in total
  1. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. … It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.

  2. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain. … It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile.

  3. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Development is assumed to have been discontinued. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.

  4. Drug

    Tulobuterol

    go.drugbank.com/drugs/DB12248
    Investigational

    Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

    Categories: Agents to Treat Airway Disease
  5. Drug

    Pipobroman

    go.drugbank.com/drugs/DB00236
    Approved

    An antineoplastic agent that acts by alkylation.

  6. Drug

    Zinc glycinate

    go.drugbank.com/drugs/DB14493
    Investigational

    Glycoprotein marker of gastrointestinal cancer.

    Mixtures: Corvite FE, Corvite FE
  7. Drug

    Sodium cation

    go.drugbank.com/drugs/DB14516
    Investigational

    Mixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML, PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1500 ML
  8. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion

  9. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada. … Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion.

  10. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.